The drug is now called GBR500 and is a monoclonal antibody to treat Crohn’s and other chronic autoimmune disorders. It is a first-in-class antagonist of the VLA-2 (alpha2-beta1) integrin. GBR500 has completed a phase I study in the U.S. and the treatment has been well tolerated.
Glenmark will receive an upfront fee of $50 million; $25 million will be paid at the closing of the deal. The remainder is contingent upon Sanofi’s "positive assessment of certain data.” This data will be provided by Glenmark.
Glenmark could also receive success-based development, regulatory and commercial milestone payments worth over $600 million, plus royalties, says Pharma Times. Sanofi will get exclusive marketing rights in North America, Europe, Japan, Mexico, Argentina, Chile and Uruguay, and co-marketing or co-promotion rights in Brazil, Russia, Australia and New Zealand. Glenmark will retain rights in India and the rest of the world.